紫杉醇单药及联合顺铂治疗老年晚期非小细胞肺癌的临床观察

目的观察紫杉醇（TAX）单药与TAX＋顺铂（DDP）治疗老年晚期NSCLC的疗效和不良反应。方法经病理学或细胞学证实的58例晚期非小细胞肺癌随机分为两组，A组：应用TAX单药化疗，B组：TAX＋DDP联合化疗，21天为一个周期，均治疗2周期以上。观察经两方案治疗后的缓解率（RR）、临床获益率（CR＋PR＋SD）、1年生存率和不良反应。结果A组及B组的有效率分别为31．0％和37．9％（P=0．22）；临床获益率（CR＋PR＋SD）分别为72．4％和79．3％（P=0．73）；1年生存率分别为43．3％和46．4％（P=0．52）；单药组的消化道毒性、骨髓毒性及肾脏损伤均显著低于联合组（P〈0．05）。结论紫杉醇单药或联合顺铂均是治疗老年晚期NSCLC的较好方案，二者疗效相似，单药紫杉醇毒副反应更少见，较易为老年患者接受。

Clinical observation of effect of TAX alone Versus TAX plus Cisplatin for Treatment of Elderly Patients with Non-small Cell Lung Cancer

Objective To explore the effects and toxicities of TAX alone and TAX plus Cisplatin in treatment of elderly NSCLC patients. Methods A total of 58 patients with advanced elderly NSCLC patients diagnosed by pathology were randomly divided into two groups. Group A and Group B. In Group A Only TAX was given. In Group B TAX and DDPwere given with 21 days as a cycle. All patients received at least two-cycle treatment. To evaluate Response rates (RR) and clinical Response rates(CR PR SD) 1-year survival rate and toxicoty.Results The response rate of patients were 31.0% in A group and 37.9% in B group (P=0.22).The clinical Response rates(CR PR SD) of patients were 72.4% and 79.3% (P=0.73); The 1-year survival rate were 43.3% and 46.4% (P=0.52). The rates of nausea/vomiting, myelo-supression and kidney damage in A group were lower than those in B group (P<0.05). Conclusion TAX alone and TAX plus Cisplatin are both effective for elderly advanced NSCLC. But the toxicities are lower in TAX alone group which is favorable for the elderly.